Sodium-iodine symporter gene expression controlled by the EGR-1 promoter: biodistribution, imaging and in vitro radionuclide therapy with Na(131)I

The objective of this study is to explore the feasibility of radioiodine treatment for cervical cancer using the early growth response (Egr-1) promoter to control sodium-iodine symporter (hNIS) gene expression. The hNIS gene was previously transfected into Hela cells under the control of either the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Technology in cancer research & treatment 2015-02, Vol.14 (1), p.61-69
Hauptverfasser: Tang, Jun, Wang, Xiaoxia, Xu, Yuanqi, Shi, Yizhen, Liu, Zengli, Yang, Yi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 69
container_issue 1
container_start_page 61
container_title Technology in cancer research & treatment
container_volume 14
creator Tang, Jun
Wang, Xiaoxia
Xu, Yuanqi
Shi, Yizhen
Liu, Zengli
Yang, Yi
description The objective of this study is to explore the feasibility of radioiodine treatment for cervical cancer using the early growth response (Egr-1) promoter to control sodium-iodine symporter (hNIS) gene expression. The hNIS gene was previously transfected into Hela cells under the control of either the cytomegalovirus (CMV) or Egr-1 promoters. Na(125)I uptake was measured in the presence or absence of NaClO4. Na(125)I efflux was measured. The effects of external beam radiation on iodine uptake and retention were studied. The cytotoxic effects of (131)I were measured by clonogenic assay. The Na(125)I biodistribution was obtained using mice bearing control and transfected cells. The %ID/g of tumor and major organs were obtained for a range of times up to 48 hours post injection and the ratio of tumor to non-tumor activity (T/NT) was calculated. Tumors were imaged with Na(131)I and (99m)TcO4 (-), and the ratio of tumor to background activity (T/B) was calculated. Na(125)I uptake in Hela cells was minimal in the absence of hNIS. Uptake in the transfected cells was strong, and could be blocked by NaClO4. The iodine uptake of Hela-Egr-1-hNIS cells increased after the irradiation, and the magnitude of this effect approximately matched the radiation dose delivered. The efflux of 125I was affected by neither the promoter sequence nor pre-irradiation. (131)I reduced the clonogenic survival of symporter expressing cells, relative to the parental line. The effect was greatest in cells where hNIS was driven by the CMV promoter. Tumors formed from Hela-Egr-1-hNIS concentrated Na(125)I over a 12 hour period, in contrast to untransfected cells. These tumors could also be successfully imaged using either Na(131)I or (99m)TcO4 (-). (131)I uptake peaked at 4h, while (99m)TcO4 (-) accumulated over approximately 20 hours. In vivo uptake of (131)I and (99m)TcO4 (-) was slightly higher in cells transfected with the Egr-1 promoter, compared to CMV. Hela-Egr-1-hNIS cells demonstrate highly enhanced iodine uptake, and this effect is further augmented by radiation, creating a positive feedback loop which may bolster radionuclide therapy in vivo.
doi_str_mv 10.7785/tcrt.2012.500396
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1652451047</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1652451047</sourcerecordid><originalsourceid>FETCH-LOGICAL-p563-bf66f724d18aba28d01538d990fbaa2a4d6d2bbc5d4633e81e7ede457dae65263</originalsourceid><addsrcrecordid>eNo1kEtLAzEUhYMgtlb3riTLCk7NY5KZupNSa6EoaPclmdy2kXmZZNT5G_5iU6yrw-We88E5CF1RMsmyXNyFwoUJI5RNBCF8Kk_QkArOE8J5PkDn3r8TwqTk9AwNWMpFmgk-RD9vjbFdldgoNWDfV23jAji8g3jCd-vAe9vUuGjq4JqyBIN1j8Me8HzxmlDcuqZqYuAe6wPDB2d1F2LiFttK7Wy9w6o22Nb400YAdsrEZ1eU1sAB41Tb4y8b9vhZjSmnN8sLdLpVpYfLo47Q-nG-nj0lq5fFcvawSloheaK3Um4zlhqaK61Ybkhsm5vplGy1UkylRhqmdSFMKjmHnEIGBlKRGQVSMMlHaPyHjQ0-OvBhU1lfQFmqGprOb2h0pYKSNIvW66O10xWYTetiNddv_mfkv2bVdbw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1652451047</pqid></control><display><type>article</type><title>Sodium-iodine symporter gene expression controlled by the EGR-1 promoter: biodistribution, imaging and in vitro radionuclide therapy with Na(131)I</title><source>MEDLINE</source><source>Sage Journals GOLD Open Access 2024</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Tang, Jun ; Wang, Xiaoxia ; Xu, Yuanqi ; Shi, Yizhen ; Liu, Zengli ; Yang, Yi</creator><creatorcontrib>Tang, Jun ; Wang, Xiaoxia ; Xu, Yuanqi ; Shi, Yizhen ; Liu, Zengli ; Yang, Yi</creatorcontrib><description>The objective of this study is to explore the feasibility of radioiodine treatment for cervical cancer using the early growth response (Egr-1) promoter to control sodium-iodine symporter (hNIS) gene expression. The hNIS gene was previously transfected into Hela cells under the control of either the cytomegalovirus (CMV) or Egr-1 promoters. Na(125)I uptake was measured in the presence or absence of NaClO4. Na(125)I efflux was measured. The effects of external beam radiation on iodine uptake and retention were studied. The cytotoxic effects of (131)I were measured by clonogenic assay. The Na(125)I biodistribution was obtained using mice bearing control and transfected cells. The %ID/g of tumor and major organs were obtained for a range of times up to 48 hours post injection and the ratio of tumor to non-tumor activity (T/NT) was calculated. Tumors were imaged with Na(131)I and (99m)TcO4 (-), and the ratio of tumor to background activity (T/B) was calculated. Na(125)I uptake in Hela cells was minimal in the absence of hNIS. Uptake in the transfected cells was strong, and could be blocked by NaClO4. The iodine uptake of Hela-Egr-1-hNIS cells increased after the irradiation, and the magnitude of this effect approximately matched the radiation dose delivered. The efflux of 125I was affected by neither the promoter sequence nor pre-irradiation. (131)I reduced the clonogenic survival of symporter expressing cells, relative to the parental line. The effect was greatest in cells where hNIS was driven by the CMV promoter. Tumors formed from Hela-Egr-1-hNIS concentrated Na(125)I over a 12 hour period, in contrast to untransfected cells. These tumors could also be successfully imaged using either Na(131)I or (99m)TcO4 (-). (131)I uptake peaked at 4h, while (99m)TcO4 (-) accumulated over approximately 20 hours. In vivo uptake of (131)I and (99m)TcO4 (-) was slightly higher in cells transfected with the Egr-1 promoter, compared to CMV. Hela-Egr-1-hNIS cells demonstrate highly enhanced iodine uptake, and this effect is further augmented by radiation, creating a positive feedback loop which may bolster radionuclide therapy in vivo.</description><identifier>EISSN: 1533-0338</identifier><identifier>DOI: 10.7785/tcrt.2012.500396</identifier><identifier>PMID: 24354753</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Cell Line, Tumor ; Disease Models, Animal ; Early Growth Response Protein 1 - genetics ; Female ; Gene Expression ; Humans ; Iodine Radioisotopes - therapeutic use ; Male ; Mice ; Promoter Regions, Genetic ; Radionuclide Imaging ; Sodium Iodide ; Symporters - genetics ; Technetium ; Uterine Cervical Neoplasms - diagnostic imaging ; Uterine Cervical Neoplasms - genetics ; Uterine Cervical Neoplasms - radiotherapy ; Xenograft Model Antitumor Assays</subject><ispartof>Technology in cancer research &amp; treatment, 2015-02, Vol.14 (1), p.61-69</ispartof><rights>The Author(s) 2014.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24354753$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tang, Jun</creatorcontrib><creatorcontrib>Wang, Xiaoxia</creatorcontrib><creatorcontrib>Xu, Yuanqi</creatorcontrib><creatorcontrib>Shi, Yizhen</creatorcontrib><creatorcontrib>Liu, Zengli</creatorcontrib><creatorcontrib>Yang, Yi</creatorcontrib><title>Sodium-iodine symporter gene expression controlled by the EGR-1 promoter: biodistribution, imaging and in vitro radionuclide therapy with Na(131)I</title><title>Technology in cancer research &amp; treatment</title><addtitle>Technol Cancer Res Treat</addtitle><description>The objective of this study is to explore the feasibility of radioiodine treatment for cervical cancer using the early growth response (Egr-1) promoter to control sodium-iodine symporter (hNIS) gene expression. The hNIS gene was previously transfected into Hela cells under the control of either the cytomegalovirus (CMV) or Egr-1 promoters. Na(125)I uptake was measured in the presence or absence of NaClO4. Na(125)I efflux was measured. The effects of external beam radiation on iodine uptake and retention were studied. The cytotoxic effects of (131)I were measured by clonogenic assay. The Na(125)I biodistribution was obtained using mice bearing control and transfected cells. The %ID/g of tumor and major organs were obtained for a range of times up to 48 hours post injection and the ratio of tumor to non-tumor activity (T/NT) was calculated. Tumors were imaged with Na(131)I and (99m)TcO4 (-), and the ratio of tumor to background activity (T/B) was calculated. Na(125)I uptake in Hela cells was minimal in the absence of hNIS. Uptake in the transfected cells was strong, and could be blocked by NaClO4. The iodine uptake of Hela-Egr-1-hNIS cells increased after the irradiation, and the magnitude of this effect approximately matched the radiation dose delivered. The efflux of 125I was affected by neither the promoter sequence nor pre-irradiation. (131)I reduced the clonogenic survival of symporter expressing cells, relative to the parental line. The effect was greatest in cells where hNIS was driven by the CMV promoter. Tumors formed from Hela-Egr-1-hNIS concentrated Na(125)I over a 12 hour period, in contrast to untransfected cells. These tumors could also be successfully imaged using either Na(131)I or (99m)TcO4 (-). (131)I uptake peaked at 4h, while (99m)TcO4 (-) accumulated over approximately 20 hours. In vivo uptake of (131)I and (99m)TcO4 (-) was slightly higher in cells transfected with the Egr-1 promoter, compared to CMV. Hela-Egr-1-hNIS cells demonstrate highly enhanced iodine uptake, and this effect is further augmented by radiation, creating a positive feedback loop which may bolster radionuclide therapy in vivo.</description><subject>Animals</subject><subject>Cell Line, Tumor</subject><subject>Disease Models, Animal</subject><subject>Early Growth Response Protein 1 - genetics</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Humans</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Male</subject><subject>Mice</subject><subject>Promoter Regions, Genetic</subject><subject>Radionuclide Imaging</subject><subject>Sodium Iodide</subject><subject>Symporters - genetics</subject><subject>Technetium</subject><subject>Uterine Cervical Neoplasms - diagnostic imaging</subject><subject>Uterine Cervical Neoplasms - genetics</subject><subject>Uterine Cervical Neoplasms - radiotherapy</subject><subject>Xenograft Model Antitumor Assays</subject><issn>1533-0338</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kEtLAzEUhYMgtlb3riTLCk7NY5KZupNSa6EoaPclmdy2kXmZZNT5G_5iU6yrw-We88E5CF1RMsmyXNyFwoUJI5RNBCF8Kk_QkArOE8J5PkDn3r8TwqTk9AwNWMpFmgk-RD9vjbFdldgoNWDfV23jAji8g3jCd-vAe9vUuGjq4JqyBIN1j8Me8HzxmlDcuqZqYuAe6wPDB2d1F2LiFttK7Wy9w6o22Nb400YAdsrEZ1eU1sAB41Tb4y8b9vhZjSmnN8sLdLpVpYfLo47Q-nG-nj0lq5fFcvawSloheaK3Um4zlhqaK61Ybkhsm5vplGy1UkylRhqmdSFMKjmHnEIGBlKRGQVSMMlHaPyHjQ0-OvBhU1lfQFmqGprOb2h0pYKSNIvW66O10xWYTetiNddv_mfkv2bVdbw</recordid><startdate>201502</startdate><enddate>201502</enddate><creator>Tang, Jun</creator><creator>Wang, Xiaoxia</creator><creator>Xu, Yuanqi</creator><creator>Shi, Yizhen</creator><creator>Liu, Zengli</creator><creator>Yang, Yi</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201502</creationdate><title>Sodium-iodine symporter gene expression controlled by the EGR-1 promoter: biodistribution, imaging and in vitro radionuclide therapy with Na(131)I</title><author>Tang, Jun ; Wang, Xiaoxia ; Xu, Yuanqi ; Shi, Yizhen ; Liu, Zengli ; Yang, Yi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p563-bf66f724d18aba28d01538d990fbaa2a4d6d2bbc5d4633e81e7ede457dae65263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Cell Line, Tumor</topic><topic>Disease Models, Animal</topic><topic>Early Growth Response Protein 1 - genetics</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Humans</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Male</topic><topic>Mice</topic><topic>Promoter Regions, Genetic</topic><topic>Radionuclide Imaging</topic><topic>Sodium Iodide</topic><topic>Symporters - genetics</topic><topic>Technetium</topic><topic>Uterine Cervical Neoplasms - diagnostic imaging</topic><topic>Uterine Cervical Neoplasms - genetics</topic><topic>Uterine Cervical Neoplasms - radiotherapy</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tang, Jun</creatorcontrib><creatorcontrib>Wang, Xiaoxia</creatorcontrib><creatorcontrib>Xu, Yuanqi</creatorcontrib><creatorcontrib>Shi, Yizhen</creatorcontrib><creatorcontrib>Liu, Zengli</creatorcontrib><creatorcontrib>Yang, Yi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Technology in cancer research &amp; treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tang, Jun</au><au>Wang, Xiaoxia</au><au>Xu, Yuanqi</au><au>Shi, Yizhen</au><au>Liu, Zengli</au><au>Yang, Yi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sodium-iodine symporter gene expression controlled by the EGR-1 promoter: biodistribution, imaging and in vitro radionuclide therapy with Na(131)I</atitle><jtitle>Technology in cancer research &amp; treatment</jtitle><addtitle>Technol Cancer Res Treat</addtitle><date>2015-02</date><risdate>2015</risdate><volume>14</volume><issue>1</issue><spage>61</spage><epage>69</epage><pages>61-69</pages><eissn>1533-0338</eissn><abstract>The objective of this study is to explore the feasibility of radioiodine treatment for cervical cancer using the early growth response (Egr-1) promoter to control sodium-iodine symporter (hNIS) gene expression. The hNIS gene was previously transfected into Hela cells under the control of either the cytomegalovirus (CMV) or Egr-1 promoters. Na(125)I uptake was measured in the presence or absence of NaClO4. Na(125)I efflux was measured. The effects of external beam radiation on iodine uptake and retention were studied. The cytotoxic effects of (131)I were measured by clonogenic assay. The Na(125)I biodistribution was obtained using mice bearing control and transfected cells. The %ID/g of tumor and major organs were obtained for a range of times up to 48 hours post injection and the ratio of tumor to non-tumor activity (T/NT) was calculated. Tumors were imaged with Na(131)I and (99m)TcO4 (-), and the ratio of tumor to background activity (T/B) was calculated. Na(125)I uptake in Hela cells was minimal in the absence of hNIS. Uptake in the transfected cells was strong, and could be blocked by NaClO4. The iodine uptake of Hela-Egr-1-hNIS cells increased after the irradiation, and the magnitude of this effect approximately matched the radiation dose delivered. The efflux of 125I was affected by neither the promoter sequence nor pre-irradiation. (131)I reduced the clonogenic survival of symporter expressing cells, relative to the parental line. The effect was greatest in cells where hNIS was driven by the CMV promoter. Tumors formed from Hela-Egr-1-hNIS concentrated Na(125)I over a 12 hour period, in contrast to untransfected cells. These tumors could also be successfully imaged using either Na(131)I or (99m)TcO4 (-). (131)I uptake peaked at 4h, while (99m)TcO4 (-) accumulated over approximately 20 hours. In vivo uptake of (131)I and (99m)TcO4 (-) was slightly higher in cells transfected with the Egr-1 promoter, compared to CMV. Hela-Egr-1-hNIS cells demonstrate highly enhanced iodine uptake, and this effect is further augmented by radiation, creating a positive feedback loop which may bolster radionuclide therapy in vivo.</abstract><cop>United States</cop><pmid>24354753</pmid><doi>10.7785/tcrt.2012.500396</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1533-0338
ispartof Technology in cancer research & treatment, 2015-02, Vol.14 (1), p.61-69
issn 1533-0338
language eng
recordid cdi_proquest_miscellaneous_1652451047
source MEDLINE; Sage Journals GOLD Open Access 2024; EZB-FREE-00999 freely available EZB journals
subjects Animals
Cell Line, Tumor
Disease Models, Animal
Early Growth Response Protein 1 - genetics
Female
Gene Expression
Humans
Iodine Radioisotopes - therapeutic use
Male
Mice
Promoter Regions, Genetic
Radionuclide Imaging
Sodium Iodide
Symporters - genetics
Technetium
Uterine Cervical Neoplasms - diagnostic imaging
Uterine Cervical Neoplasms - genetics
Uterine Cervical Neoplasms - radiotherapy
Xenograft Model Antitumor Assays
title Sodium-iodine symporter gene expression controlled by the EGR-1 promoter: biodistribution, imaging and in vitro radionuclide therapy with Na(131)I
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A00%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sodium-iodine%20symporter%20gene%20expression%20controlled%20by%20the%20EGR-1%20promoter:%20biodistribution,%20imaging%20and%20in%20vitro%20radionuclide%20therapy%20with%20Na(131)I&rft.jtitle=Technology%20in%20cancer%20research%20&%20treatment&rft.au=Tang,%20Jun&rft.date=2015-02&rft.volume=14&rft.issue=1&rft.spage=61&rft.epage=69&rft.pages=61-69&rft.eissn=1533-0338&rft_id=info:doi/10.7785/tcrt.2012.500396&rft_dat=%3Cproquest_pubme%3E1652451047%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1652451047&rft_id=info:pmid/24354753&rfr_iscdi=true